Pharmacokinetics of HM-3 After Intravitreal Administration in Mice

References

• Seddon JM, Reynolds R, Yu Y, Daly MJ, Rosner B. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology 2011;118:2203–2211
   PubMed Web of Science ®Google Scholar
• Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med 2000;342:483–492
   PubMed Web of Science ®Google Scholar
• Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet 2012;379:1728–1738
   PubMed Web of Science ®Google Scholar
• Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 2008;27:372–390
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham Jr. ET, Feinsod M, Guyer DR, Group VISiONCT. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–2816
   Google Scholar
• Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin 2011; 27:1465–1475
   PubMed Web of Science ®Google Scholar
• Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Invest Drugs 2009;18:1573–1580
   PubMed Web of Science ®Google Scholar
• Cloutier F, Lawrence M, Goody R, Lamoureux S, Al-Mahmood S, Colin S, et al. Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration. Invest Ophthalmol Vis Sci 2012;53:1195–1203
   PubMed Web of Science ®Google Scholar
• Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol 2010;21:178–183
   PubMed Web of Science ®Google Scholar
• Gutfleisch M, Heimes B, Schumacher M, Dietzel M, Lommatzsch A, Bird A, et al. Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD. Eye 2011;25:1181–1186
   PubMedGoogle Scholar
• Akkoyun I, Karabay G, Haberal N, Dagdeviren A, Yilmaz G, Oto S, et al. Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model. Acta Ophthalmol 2012;90:564–570
   PubMedGoogle Scholar
• Kociok N, Joussen AM. Varied expression of functionally important genes of RPE and choroid in the macula and in the periphery of normal human eyes. Graefes Arch Clin Exp Ophthalmol 2007;245:101–113
   PubMed Web of Science ®Google Scholar
• Santulli RJ, Kinney WA, Ghosh S, Decorte BL, Liu L, Tuman RW, et al. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther 2008;324:894–901
   PubMed Web of Science ®Google Scholar
• Tolentino MJ. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. Curr Mol Med 2009;9:973–981
   PubMed Web of Science ®Google Scholar
• Heckmann D, Meyer A, Laufer B, Zahn G, Stragies R, Kessler H. Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor. Chembiochem 2008;9:1397–1407
   PubMed Web of Science ®Google Scholar
• Zeng ZZ, Yao H, Staszewski ED, Rockwood KF, Markwart SM, Fay KS, et al. Alpha(5)beta(1) integrin ligand PHSRN induces invasion and alpha(5) mRNA in endothelial cells to stimulate angiogenesis. Transl Oncol 2009;2:8–20
   PubMed Web of Science ®Google Scholar
• Zhou K, Zheng X, Xu HM, Zhang J, Chen Y, Xi T, et al. Studies of poly(ethylene glycol) modification of HM-3 polypeptides. Bioconjug Chem 2009;20:932–936
   PubMedGoogle Scholar
• Xu HM, Yin RT, Chen LS, Siraj S, Huang XF, Wang M, et al. An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo. Bioconjug Chem 2008;19:1980–1986
   PubMedGoogle Scholar
• Xu HM. HM-3, Angiogenesis Inhibitor Preparative Method and Application. China Patent 1830487, 13 September 2006
   Google Scholar
• Zhu B, Xu HM, Zhao L, Huang X, Zhang F. Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa. J Biochem 2010;148:341–347
   PubMedGoogle Scholar
• Liu Z, Li W, Xu HM, Huang X, Pan L, Ren Y, et al. In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated antitumor polypeptide. Curr Pharm Des 2012;18:1655–1662
   PubMedGoogle Scholar
• Zhu B, Zhang FG, Xu HM. Research of McAb-based competitive ELISA for detecting HM-3 residues in serum. Pharmaceut Biotechnol 2010;17:499–503
   Google Scholar
• Kim SJ, Adams NA, Toma HS, Belair ML, Thorne JE, Green WR, et al. Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina 2008;28:595–605
   PubMed Web of Science ®Google Scholar
• Foulds WS, Allan D, Moseley H, Kyle PM. Effect of intravitreal hyaluronidase on the clearance of tritiated water from the vitreous to the choroid. Br J Ophthalmol 1985;69:529–532
   PubMed Web of Science ®Google Scholar
• Park J, Bungay PM, Lutz RJ, Augsburger JJ, Millard RW, Sinha Roy A, et al. Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release 2005;105:279–295
   PubMed Web of Science ®Google Scholar
• Missel PJ. Hydraulic flow and vascular clearance influences on intravitreal drug delivery. Pharm Res 2002;19:1636–1647
   PubMed Web of Science ®Google Scholar
• Xu J, Heys JJ, Barocas VH, Randolph TW. Permeability and diffusion in vitreous humor: implications for drug delivery. Pharm Res 2000;17:664–669
   PubMed Web of Science ®Google Scholar
• Heegaard S, Jensen OA, Prause JU. Structure and composition of the inner limiting membrane of the retina. SEM on frozen resin-cracked and enzyme-digested retinas of Macaca mulatta. Graefes Arch Clin Exp Ophthalmol 1986;224:355–360
   PubMedGoogle Scholar
• Pitkanen L, Pelkonen J, Ruponen M, Ronkko S, Urtti A. Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model. AAPS J 2004;6:72–80
   Google Scholar
• Peeters L, Sanders NN, Braeckmans K, Boussery K, Van de Voorde J, De Smedt SC, et al. Vitreous: a barrier to nonviral ocular gene therapy. Invest Ophthalmol Vis Sci 2005;46:3553–3561
   PubMed Web of Science ®Google Scholar
• Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814–2823
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz JG. The blood-retinal barriers system. Basic concepts and clinical evaluation. Exp Eye Res 2004;78:715–721
   PubMed Web of Science ®Google Scholar
• Steuer H, Jaworski A, Stoll D, Schlosshauer B. In vitro model of the outer blood-retina barrier. Brain Res Brain Res Protoc 2004;13:26–36
   PubMedGoogle Scholar
• Friedrich S, Cheng YL, Saville B. Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume. Curr Eye Res 1997;16:663–669
   PubMed Web of Science ®Google Scholar